Flunitrazepam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Flunitrazepam — Rohypnol, roofies — is a synthetic depressant of the benzodiazepine class. It is among the most potent benzodiazepines ever marketed, active at doses one-tenth those of diazepam.[1] Flunitrazepam is a positive allosteric modulator at GABA-A receptors, producing its effects by amplifying the brain's primary inhibitory signaling system.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Developed by Hoffmann-La Roche in the 1960s, flunitrazepam was first marketed in Switzerland in the early 1970s for severe insomnia and preoperative sedation.[2] By the 1990s it had become the most prominent agent of drug-facilitated sexual assault, prompting the US Drug-Induced Rape Prevention and Punishment Act of 1996.[3] It was never approved in the United States and has been withdrawn from most European markets, though it remains prescribed in parts of Latin America and Asia.
Subjective effects include deep sedation, anterograde amnesia, anxiolysis, muscle relaxation, and dose-dependent euphoria. The experience is defined by the speed and completeness of the amnestic curtain — memory suppression sets in before sedation becomes overwhelming, creating a window of disinhibited wakefulness the user cannot later recall.[4][5] Delusions of sobriety, dangerous behavioral disinhibition, and next-day cognitive impairment are characteristic unsought effects.
Flunitrazepam produces rapid physical dependence and can cause death as the sole intoxicant — respiratory depression is the lethal mechanism.[6] Alcohol co-ingestion reduces the lethal threshold to roughly one-third of the sole-agent concentration, and opioid combinations produce respiratory failure not reversible by naloxone.[7] Six decades of clinical and forensic research make flunitrazepam one of the most thoroughly characterized benzodiazepines.[1]
History[edit]
Discovery
Flunitrazepam was synthesized in the 1960s at Hoffmann-La Roche's Basel laboratories under the research code Ro 5-4200.[2] The compound emerged from the same benzodiazepine program that produced chlordiazepoxide, diazepam, and nitrazepam. Its 7-nitro and 2'-fluoro substitutions were engineered to boost receptor affinity beyond existing hypnotics, yielding a compound active at a fraction of diazepam's dose.[1]
Clinical adoption
Marketed as Rohypnol in Switzerland in the early 1970s, flunitrazepam was licensed for severe insomnia and preoperative sedation, then approved across Europe, Latin America, and parts of Asia.[2] By 1980, pharmacological reviews described it as superior to older hypnotics for insomnia management, with clinical doses of 1–2 mg producing reliable sleep onset within 15–30 minutes.[8] It was never submitted for FDA approval in the United States — a decision that later shaped its unique legal trajectory.
Drug-facilitated assault and regulatory response
Through the 1990s, flunitrazepam became a prominent agent of drug-facilitated sexual assault, particularly in the United States, where it arrived through illicit importation.[9] Its potent amnesia, rapid onset, and colorless dissolution made covert administration straightforward. Congress responded with the Drug-Induced Rape Prevention and Punishment Act of 1996, imposing 20-year sentences for distributing a controlled substance to facilitate violent crime.[3] Roche reformulated the tablets with blue dye, reduced strength from 2 mg to 1 mg, and slowed dissolution[2] — countermeasures that applied only to the branded product. From the 2000s onward, France, Spain, Norway, Germany, and the United Kingdom withdrew Rohypnol from active markets.
The street name roofies — and its verb form roofied — entered mainstream English in the 1990s as shorthand for covert drugging, becoming one of the few drug slang terms adopted into general media and legal discourse. Rohypnol itself carries more cultural weight than flunitrazepam: the trade name is synonymous with drink-spiking in public consciousness. The compound retains significance in forensic toxicology as a benchmark for detection methodology and in receptor pharmacology as the prototypical radioligand for characterizing GABA-A benzodiazepine binding sites.[10]
Chemistry[edit]
Structural class
Flunitrazepam belongs to the nitrobenzodiazepine subclass of the 1,4-benzodiazepine family, sharing its core scaffold with diazepam, nitrazepam, and clonazepam. Two substitutions set it apart: a nitro group at the 7-position of the fused benzene ring and a fluorine atom at the 2'-position of the pendant phenyl ring. A methyl group occupies the 1-position nitrogen.
This combination of 7-nitro and 2'-fluoro produces substantially higher receptor affinity than chloro-substituted or unsubstituted analogs, underpinning flunitrazepam's potency at sub-milligram to low-milligram doses.[1]
Molecular properties
| Molecular formula | C₁₆H₁₂FN₃O₃ |
| Molecular weight | 313.28 g/mol |
The molecule consists of a seven-membered diazepinone ring fused to a substituted benzene ring. A carbonyl group at C-2 and an imine at C-4 define the 2-one benzodiazepine series. The 5-position phenyl ring bearing the ortho-fluorine extends perpendicular to the benzodiazepine plane.
Stereochemistry
Flunitrazepam lacks a classical chirality center. The diazepine ring adopts a boat-like puckered geometry, but ring inversion is rapid at body temperature, and no clinically relevant stereoisomerism has been documented.citation needed The compound is manufactured and used as a single molecular entity.
Physical properties
In pure form, flunitrazepam is a white crystalline powder with reported melting points of 166–172°C depending on crystalline form.citation needed It exists predominantly in the un-ionized form at physiological pH, facilitating rapid absorption across biological membranes and contributing to its high oral bioavailability.[11]
Pharmacology[edit]
Mechanism of action
Flunitrazepam is a positive allosteric modulator at the GABA-A, binding at the benzodiazepine site on the receptor complex. When GABA — the brain's primary inhibitory neurotransmitter — activates these receptors, flunitrazepam amplifies the response, increasing the frequency of chloride channel opening and strengthening inhibitory signaling throughout the central nervous system.[1]
This amplification does not activate the receptor on its own — it potentiates whatever GABA activity is already present. The result is a general dampening of neural excitability that manifests as sedation, amnesia, anxiolysis, and muscle relaxation. Flunitrazepam's affinity for the GABA-A receptor exceeds that of most benzodiazepines, including diazepam and nitrazepam, accounting for its potency at doses of 1–2 mg.[1]
Pharmacokinetics
Oral bioavailability is high at 80% or greater, with onset of effects within 15–30 minutes of ingestion.[2][8] Plasma protein binding is approximately 96%, predominantly to albumin.[12]
The half-life averages 22 hours (range 16–35 hours across studies),[13][14] but the deeper sedative effects resolve within 4–8 hours — a disparity explained by redistribution from the brain during the distribution phase. Residual drug persists in the body long after subjective effects have faded, contributing to next-day impairment.
Metabolism
Flunitrazepam is metabolized through two main liver pathways.[15][16] The first produces desmethylflunitrazepam, a pharmacologically active metabolite that extends the drug's functional duration. The second produces 3-hydroxyflunitrazepam. Both pathways are susceptible to inhibition by common medications including azole antifungals and HIV protease inhibitors.[16]
The forensically important metabolite 7-aminoflunitrazepam — formed by reduction of the nitro group — serves as the primary marker for detecting flunitrazepam use in urine and postmortem blood.[17]
Genetic variation in liver enzymes alters the ratio of metabolites but does not substantially change overall clinical effects, because alternative metabolic pathways compensate.[18]
Neuroscience[edit]
Where it acts
Flunitrazepam potentiates GABA-A receptors across cortical, limbic, and brainstem circuits, producing its diverse effects through different brain regions. Sedation arises from enhanced inhibition in thalamic and cortical circuits, reducing sensory throughput and promoting sleep onset.[19]
Amnesia reflects suppression of hippocampal activity required for memory consolidation — flunitrazepam's particular potency here may explain why its amnestic effects exceed those of most benzodiazepines at comparable doses.[4] Respiratory depression, the lethal mechanism in overdose, results from excessive inhibition in brainstem breathing centers,[6] an effect that compounds dangerously with opioid-mediated depression in overlapping brainstem regions.[7][20]
Tolerance and adaptation
Repeated use triggers adaptive changes at GABA-A receptors: the receptor becomes less responsive to the drug through functional uncoupling, and receptor numbers on the cell surface decline.[21] These changes develop at different rates for different effects — tolerance to sedation appears within days, while tolerance to muscle relaxation develops minimally.[22]
When the drug is withdrawn, the adapted receptors leave the brain in a state of excessive excitability, producing rebound effect anxiety, insomnia, and in severe cases seizures.[21]
Several aspects of flunitrazepam's neuroscience remain unresolved. The dose-dependent euphoria — maximal at approximately 1.25 mg, suppressed at higher doses by overwhelming sedation[23] — is pharmacologically unusual and may involve dopamine release in reward circuits, but this has not been directly investigated.
Subjective Effects[edit]
Flunitrazepam imposes an experience dominated by erasure — of wakefulness, of anxiety, of memory. At low doses, warm sedation and anxiolysis emerge alongside a window of mild euphoria. As dose increases, anterograde amnesia becomes the defining feature: memory recording shuts down before subjective sedation becomes overwhelming, producing a period of disinhibited wakefulness the user cannot subsequently recall.[4][5] Set and setting profoundly shape what happens during this amnestic window — clinical contexts produce passive sedation, while unstructured environments invite dangerous impulsivity.
Within the benzodiazepine class, flunitrazepam sits closest to midazolam in its amnesia-to-sedation ratio but exceeds it in duration and euphorigenic potential. Compared with diazepam, it produces qualitatively deeper sedation and more complete memory suppression at roughly one-tenth the dose.[1]
Effect Grid
Pronounced sedation and hypnosis dominate the experience. Anterograde amnesia becomes reliable at doses of 1 mg and above — events occurring after ingestion may be partially or completely unrecallable. The euphorigenic window is maximized around 1.25 mg with rapid onset, producing a balance of cognitive euphoria and anxiolysis that distinguishes flunitrazepam from lower-potency benzodiazepines. Disinhibition becomes apparent; delusions of sobriety may begin to emerge.
Motor control impairment is significant — coordination is visibly affected, and fine motor tasks become difficult. Muscle relaxation is robust. Bodily heaviness increases. Dizziness is possible, particularly when standing.
Amnesia onset characteristically precedes the individual's subjective awareness of impairment. This dissociation between actual and perceived intoxication is a defining safety concern at common doses.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Proprioceptive distortion · Visual haze / noise · Depth perception distortion · Visual processing suppression
Visual processing suppression
Dizziness · Physical fatigue · Nystagmus (eye wobbles) · Breathing alteration · Dry mouth · Body high · Headache · Laughter fits · Nausea · Heart rate perception changes · Pain suppression · Sexual arousal enhancement · Sexual arousal suppression · Appetite enhancement · Yawning · Nausea suppression · Temperature dysregulation · Vomiting · Restlessness · Bodily dissociation
Breathing alteration · Dry mouth · Body high · Headache · Laughter fits · Nausea · Heart rate perception changes · Pain suppression · Sexual arousal enhancement · Sexual arousal suppression · Appetite enhancement · Yawning · Nausea suppression · Vomiting · Restlessness · Bodily dissociation
Analysis suppression · Cognitive fatigue · Focus suppression · Memory fragmentation · Thought deceleration · Confusion · Language suppression · Motivation suppression · Pattern recognition suppression · Suggestibility enhancement · Thought disorganization · Compulsive redosing urge · Creativity suppression · Novelty suppression · Cognitive euphoria · Immersion suppression · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Memory fragmentation · Thought deceleration · Confusion · Language suppression · Motivation suppression · Pattern recognition suppression · Thought disorganization · Compulsive redosing urge · Creativity suppression · Novelty suppression · Cognitive euphoria · Immersion suppression · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Dysphoria · Emotional lability · Irritability · Paranoia
Emotional susceptibility · Trust enhancement · Sociability enhancement · Social disconnection · Depersonalization · Derealization · Sociability suppression · Communication enhancement · Social connection · Cognitive disconnection
Depersonalization · Derealization · Sociability suppression · Communication enhancement · Social connection · Cognitive disconnection
Timeline
Gradual onset of relaxation and mild anxiolysis. A sense of calm settles in before overt sedation becomes apparent. Subtle muscle relaxation may be noticed in the jaw and shoulders.
Full sedation, anterograde amnesia, and muscle relaxation. Disinhibition and cognitive euphoria (at medium doses) are maximal. Motor control impairment is pronounced.
Sedation gradually lifts but cognitive impairment, motor coordination deficits, and thought deceleration persist well beyond subjective awareness of recovery. Decision-making remains impaired.
Residual psychomotor impairment, drowsiness, and cognitive fog may persist into the next day. Reaction times remain measurably slowed.
⚠ Do not drive or operate machinery for at least 12 hours after ingestion — residual impairment persists well beyond subjective sedation.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · ethanol · barbiturates
Toxicity
Acute toxicity
Flunitrazepam can cause death as the sole intoxicant. Eight deaths documented in a single Australian jurisdiction over two years demonstrated this directly — four from flunitrazepam alone, four from flunitrazepam combined with alcohol.[6] Autopsy revealed no organ damage in any case. The lethal mechanism is respiratory depression: excessive suppression of brainstem breathing centers.[1]
Alcohol co-ingestion substantially reduces the lethal threshold — deaths in the alcohol-positive group occurred at drug concentrations roughly one-third of those in the flunitrazepam-only group.[6] A separate fatal case involving combined flunitrazepam and triazolam confirmed the lethality of benzodiazepine combinations.[24]
No human lethal dose or formal therapeutic index data have been published.safety citation needed
Chronic toxicity
No organ-specific chronic damage has been characterized in published human literature. The absence of organ pathology in overdose fatalities[6] indicates that toxicity is primarily functional — affecting breathing and consciousness — rather than structural. Long-term risks center on dependence, cognitive impairment, and fall-related injury.
Psychological risks
Anterograde amnesia is the most significant psychological effect. At therapeutic doses (1–2 mg), flunitrazepam produces reliable memory blackouts for events occurring after ingestion.[4] Alcohol potentiates this amnesia and creates dual vulnerability: individuals may engage in dangerous behavior they cannot recall while simultaneously being vulnerable to exploitation.[25][5]
Forensic case studies document associations between flunitrazepam intoxication and violent behavior, impulsive decisions, and profound disinhibition — particularly with concurrent alcohol.[25][26] Delusions of sobriety — the subjective belief of normal functioning despite measurable impairment — compound the risk during intoxication.[5]
Research with high-dose benzodiazepine users confirms that both victimization and perpetration of violence during amnestic episodes are common experiences.[5]
Tolerance and dependence
Tolerance develops rapidly and unevenly: tolerance to sedation appears within days, tolerance to sleep effects over one to two weeks, and tolerance to muscle relaxation minimally or not at all.[22] Cross-tolerance exists with all benzodiazepines, alcohol, and barbiturates.
Physical dependence was confirmed in primates: withdrawal seizures occurred in 1 of 4 animals after 9 days and 3 of 4 after 18 days of daily use.[22] In humans, benzodiazepine withdrawal produces anxiety, insomnia, sensory hypersensitivity, unsteadiness, and in severe cases seizures.[21] Approximately one-third of long-term users experience withdrawal even with gradual tapering.[21]
Benzodiazepine withdrawal can be life-threatening. Abrupt discontinuation after regular use may precipitate seizures. Tapering under medical supervision is essential.
Flunitrazepam ranks among the highest-abuse-potential benzodiazepines: in one study, 92.9% of benzodiazepine abusers in an opioid maintenance program selected it as their primary agent — exceeding diazepam (54.3%) and oxazepam (38.6%).[27] Oral, intranasal, and intravenous abuse routes are documented.[27][28] Systematic assessments rank it highly on reinforcement, abuse prevalence, and overdose lethality.[29]
Drug interactions
Opioids
The combination with opioids — particularly buprenorphine — has caused multiple documented deaths.[7] The interaction is pharmacodynamic: flunitrazepam does not alter buprenorphine's metabolism or brain distribution.[30][20] Buprenorphine's built-in ceiling on respiratory depression is overwhelmed by concurrent GABAergic suppression. This combination is not reversed by naloxone due to buprenorphine's tight receptor binding.[7]
Alcohol
Synergistic respiratory and CNS depression. In the Australian fatal case series, co-present alcohol reduced the lethal flunitrazepam threshold to roughly one-third of the sole-agent concentration.[6]
CYP3A4 inhibitors
Drugs that inhibit the CYP3A4 liver enzyme — including azole antifungals (ketoconazole, itraconazole), HIV protease inhibitors (ritonavir), and macrolide antibiotics (erythromycin, clarithromycin) — are expected to significantly increase flunitrazepam blood levels based on laboratory data.[16]
Heparin
Heparin increases circulating free fatty acids, displacing flunitrazepam from blood proteins and increasing the active fraction — a relevant interaction in hospital settings.[12]
Flumazenil
Flumazenil competitively reverses all GABA-A-mediated effects of flunitrazepam, but re-sedation is expected because flumazenil wears off far faster (under 90 minutes) than flunitrazepam persists (22 hours).[31] Repeated doses or continuous infusion may be needed. In mixed opioid-benzodiazepine overdoses, flumazenil alone is insufficient.[7]
Contraindications
- Breathing disorders (e.g. sleep apnea): GABAergic respiratory depression compounds existing airway compromise (absolute)inferred
- Myasthenia gravis: Drug-induced muscle relaxation worsens neuromuscular weakness (absolute)inferred
- Severe liver impairment: Reduced protein binding and impaired metabolism increase active drug levels and prolong effects (relative — dose reduction required)inferred
- History of substance use disorder: High abuse potential and strong reinforcement increase relapse risk (relative)[29]
- Pregnancy: Benzodiazepines carry birth defect risk; neonatal withdrawal is documented (absolute)inferred
- Concurrent opioid use: Synergistic respiratory depression not reversed by naloxone (absolute)[7]
- Concurrent alcohol use: Synergistic CNS depression substantially reduces lethal threshold (absolute)[6]
Harm Reduction[edit]
Forms & Identification
Pharmaceutical flunitrazepam tablets are the most common form encountered. Post-1998 branded Rohypnol tablets contain blue dye that colors light beverages when dissolved — but generic and counterfeit tablets may be white, odorless, and dissolve without visible change. The absence of blue coloring does not confirm the absence of flunitrazepam or any other sedative.
Pressed tablets sold outside pharmaceutical supply chains carry the standard risks of unregulated manufacture: variable dosing, substitution with other benzodiazepines or novel sedatives, and no quality control. Reagent testing cannot reliably distinguish flunitrazepam from other benzodiazepines — laboratory analysis is the only definitive identification method.
Guidelines
- Start with the lowest available dose — flunitrazepam is active at 1 mg and potent effects emerge rapidly
- Never combine with alcohol, opioids, or other sedatives under any circumstances
- Ensure a sober, trusted person is present throughout
- Secure the environment: remove hazards, lock doors, prevent access to vehicles
- Do not redose — amnesia may cause the user to forget they have already taken a dose
- Eat a light meal beforehand; avoid fatty foods that may alter absorption
- Set a clear plan and communicate it to the sober companion before taking the dose
- Keep flumazenil available if accessible — it can reverse benzodiazepine effects, though re-sedation is likely
Set & Setting
Flunitrazepam's potent amnesia and disinhibition make environment critical. Use in unfamiliar or uncontrolled settings dramatically increases the risk of harm — both to the user and from others. A trusted companion who remains sober is essential.
The amnestic window means the user may appear functional while forming no memories, making self-monitoring impossible. Secure, familiar environments with minimal hazards reduce the chance of injury or exploitation during this vulnerable period.
Aftercare & integration. Recovery from flunitrazepam use is primarily physical. Residual sedation, cognitive dulling, and psychomotor impairment commonly persist for 12–24 hours after dosing due to the drug's long half-life. Avoid driving, operating machinery, or making important decisions during this period.
Memory gaps are expected and can be disorienting. Speaking with anyone present during the experience may help reconstruct events. Hydration and light nutrition support recovery. If amnesia for concerning events is distressing, professional support is appropriate.
Recovery & Support
Flunitrazepam dependence requires medical management — abrupt cessation is dangerous and potentially fatal. A gradual taper supervised by a physician, often involving transition to a longer-acting benzodiazepine such as diazepam, is standard practice. Tapering schedules typically span weeks to months depending on duration and severity of use.
Support resources include addiction medicine specialists, benzodiazepine-specific peer support communities, and organizations such as the Benzodiazepine Information Coalition. For those in opioid maintenance programs — where flunitrazepam abuse is particularly prevalent[27] — integrated treatment addressing both dependencies improves outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow, shallow, or stopped breathing. Blue-tinged lips or fingernails. Unresponsiveness to voice or pain. Vomiting while unconscious or semi-conscious. Seizures.
Immediate steps:
- Call emergency services immediately if breathing slows, stops, or the person cannot be roused
- Place the person in the recovery position (on their side) to prevent choking on vomit
- Monitor breathing continuously — below 10 breaths per minute is critical
- Do not leave the person alone
- Do not induce vomiting
- Do not give stimulants (coffee, cold water) — these do not reverse benzodiazepine effects
What to tell the dispatcher: Name the substance (flunitrazepam, Rohypnol, or benzodiazepine), approximate dose if known, time of ingestion, whether alcohol or other drugs are involved, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil reverses benzodiazepine effects but wears off faster than flunitrazepam — re-sedation is likely and repeated doses may be needed.[31] In mixed overdoses involving opioids, naloxone must also be administered — flumazenil does not reverse opioid respiratory depression.[7]
Legal Status[edit]
Flunitrazepam occupies a uniquely stringent legal position among benzodiazepines. While classified as Schedule IV under the 1971 United Nations Convention on Psychotropic Substances — the same schedule as diazepam and most other benzodiazepines — individual jurisdictions have imposed substantially harsher controls in response to its association with drug-facilitated crime and high abuse potential. The compound has been withdrawn from pharmaceutical markets in most of Europe while remaining available by prescription in parts of Latin America and Asia.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (CSA), Schedule I-level penalties | Not FDA-approved. Drug-Induced Rape Prevention and Punishment Act (1996) imposes 20-year sentences for distribution to facilitate violent crime[3][32] |
| United Kingdom | Class C, Schedule 3 (Misuse of Drugs Act 1971) | More restrictively scheduled than most benzodiazepines; withdrawn from active market |
| Australia | Schedule 8 (Controlled Drug) | Highest restriction among benzodiazepines; all other benzodiazepines are Schedule 4 |
| Canada | Controlled substance | Sale banned; restricted possession |
| Germany | Anlage III (Betäubungsmittelgesetz) | Marketable under specific narcotic drug provisions; largely withdrawn from clinical use |
| France | Withdrawn from market | Rohypnol product discontinued; benzodiazepines as a class remain legal under prescription |
| Spain | Withdrawn from market | Product discontinued |
| Norway | Withdrawn from market | Product discontinued |
| International (UN) | Schedule IV (1971 Convention) | Same classification as other benzodiazepines under international treaty |
The disparity between flunitrazepam's Schedule IV classification under international treaty and the Schedule I-level penalties in the United States reflects a legislative response to drug-facilitated sexual assault rather than a pharmacological reclassification. The compound remains formally Schedule IV at the federal level; the enhanced penalties operate as sentencing provisions rather than scheduling changes.[32]
references
- [1]
- [2]
- [3]
- [4] ^abcdOtt H, Rohloff A, Aufdembrinke B, Fichte K (1988) Anterograde and retrograde amnesia after lormetazepam and flunitrazepam — Psychopharmacology series PMID:2905806
- [5]
- [6]